Lantheus Receives FTC Second Requests in Merger Review; Still Expects H1 2027 Close
Lantheus and Curium received FTC Second Requests on October 21, extending the HSR waiting period. The companies expect to respond promptly and continue to anticipate closing the merger in the first half of 2027, subject to regulatory approvals.
How this was made
The 30-second read
Why it matters
Regulatory delay adds uncertainty, potentially pressuring both LNTH and CUR shares until the review concludes.
Market read
The FTC request is a material regulatory event that could affect the timing and likelihood of the Lantheus‑Curium merger, influencing investor sentiment in the healthcare M&A space.
What to watch
Possible alternative buyers or strategic pivots if the merger stalls.
Background
The FTC's second request extends the Hart‑Scott‑Rodino waiting period, a standard step in large healthcare mergers.
Ticker impact
Lantheus Holdings received an FTC Second Request for its pending merger with Curium, extending the HSR waiting period.
likely downside as investors price in potential delay and additional regulatory risk
FTC second requests are a known hurdle that can extend the waiting period and increase the chance of deal termination.
Market effects
Potential ripple effect on the diagnostic imaging and radiopharmaceutical sector as merger timelines shift.
U.S. healthcare M&A sentiment may soften temporarily.
Limited to U.S. biotech and healthcare investors.
Counterpoint
If the FTC clears the deal quickly, the stock could rally on relief.
Key entities
- companyLantheus Holdings, Inc.
U.S. diagnostic imaging and radiopharmaceutical company.
- companyCurium Holdings, Inc.
U.S. radiopharmaceutical developer.
- regulatorFederal Trade Commission (FTC)
U.S. antitrust agency reviewing the merger.
